Experimental immune therapy offers hope for men with aggressive prostate cancer
NCT ID NCT06193486
Summary
This early-stage trial is testing a new type of immune cell therapy for men with advanced prostate cancer that has spread to bones and no longer responds to standard hormone treatments. Doctors will collect patients' own immune cells, modify them in a lab to better target prostate cancer, and then infuse them back into the body. The study aims to find the safest dose and see if this approach can help control the cancer in patients who have run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.